Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (10160)	5/23/1999 2:40:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

It leaves us waiting to see what the data reveal. IMO however, the SOC for severe meningococcal sepsis has not changed in the U.K. If it had they would be falling all over themselves to tell everyone how to save kids. Again by not letting us know what the required target was XOMA leaves loyal investors in greater doubt about what happened than if they had told us the requirement. Now that the trial has ended this is something they could certainly do. Some XOMA holders do not understand why this would be of use to other investors. Fine, but they should understand that release of this information does not result in unblinding the data. The established level of mortality was part of trial design not a result of the trial.